• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/19/25 8:41:28 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    mo-20250513
    false000076418000007641802025-05-132025-05-130000764180mo:CommonStock0.3313ParValueMember2025-05-132025-05-130000764180mo:CommonStock1.700NotesDue2025Member2025-05-132025-05-130000764180mo:CommonStock2.200NotesDue2027Member2025-05-132025-05-130000764180mo:CommonStock3.125NotesDue2031Member2025-05-132025-05-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     ____________________________________________________________________________________________________________
    FORM 8-K
    ________________________________________________________________________________________________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 13, 2025
    ________________________________________________________________________________________________________________
    ALTRIA GROUP, INC.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Virginia  1-08940  13-3260245
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  (I.R.S. Employer
    Identification No.)
    6601 West Broad Street,Richmond,Virginia23230
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (804) 274-2200
    _______________________________________________________________________________________________________________
    (Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
                   Title of each class               
    Trading SymbolsName of each exchange on which registered
    Common Stock, $0.33 1/3 par value
    MONew York Stock Exchange
    1.700% Notes due 2025
    MO25New York Stock Exchange
    2.200% Notes due 2027
    MO27New York Stock Exchange
    3.125% Notes due 2031
    MO31New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Controller Transition
    On May 13, 2025, Steven D’Ambrosia, Vice President and Controller of Altria Group, Inc. (“Altria”), announced his intention to retire as Vice President and Controller effective July 31, 2025.
    On May 15, 2025, Altria’s Board of Directors (the “Board”) elected Katie F. Patterson to become Vice President and Controller of Altria, effective upon Mr. D’Ambrosia’s retirement.
    Ms. Patterson, age 39, currently serves as Senior Director, External Reporting, Corporate and Benefits, Altria Client Services LLC, a wholly owned subsidiary of Altria, a position she has held since June 2024. Prior to this role, she served as Senior Director, Accounting and Reporting from February 2019 until June 2024. Since 2013, she has been continuously employed by Altria subsidiaries in various accounting, financial reporting, investor relations, treasury, and financial planning and analysis positions.
    As a result of her election, Ms. Patterson will become a salary band F employee effective August 1, 2025. The Compensation and Talent Development Committee of the Board set her annual base salary at $300,000, which is consistent with salaries for band F employees and market positioning for the role.
    Ms. Patterson’s annual incentive award plan, long-term incentive plan (“LTIP”) and annual equity award targets are consistent with current salary band F targets as follows: Ms. Patterson’s annual incentive award plan target will be 50% of base salary, her LTIP award target will be $112,900 over a three-year performance cycle with three cycles running concurrently and her annual equity award target will be $165,000. Ms. Patterson will be eligible to participate in the same compensation programs as Altria’s other executive officers.
    Altria’s annual incentive award plan, long-term incentives and other elements of its executive compensation program are more fully described under the “Compensation Discussion and Analysis” section of Altria’s proxy statement for its 2025 Annual Meeting of Shareholders filed with the Securities and Exchange Commission on April 3, 2025 (the “2025 Proxy Statement”).
    Equity Compensation Plans
    On May 15, 2025, Altria held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, shareholders approved Altria’s (1) 2025 Performance Incentive Plan (the “2025 PIP”) and (2) 2025 Stock Compensation Plan for Non-Employee Directors (the “2025 Non-Employee Director Plan”), each of which had been previously approved by the Board subject to shareholder approval.
    The 2025 PIP provides for annual and long-term incentive awards to eligible employees of Altria or its subsidiaries or affiliates. Awards may be paid in the form of cash, shares of common stock or any combination thereof, as determined by the Compensation and Talent Development Committee of the Board. Twenty-five million shares of Altria’s common stock are reserved for awards under the 2025 PIP.
    The 2025 Non-Employee Director Plan provides for awards to members of the Board who are not full-time employees of Altria or its subsidiaries. Awards may be paid in cash, stock options, other stock-based awards or any combination thereof, as determined by the Nominating, Corporate Governance and Social Responsibility Committee of the Board. One million shares of Altria’s common stock are reserved for awards under the 2025 Non-Employee Director Plan.
    The material terms of the 2025 PIP and the 2025 Non-Employee Director Plan are described under “Proposal 4 – Approval of the 2025 Performance Incentive Plan” and “Proposal 5 – Approval of the 2025 Stock Compensation Plan for Non-Employee Directors,” respectively, in the 2025 Proxy Statement. These descriptions are incorporated by reference in this Current Report on Form 8-K.
    The descriptions of the material terms of the 2025 PIP and the 2025 Non-Employee Director Plan are qualified in their entirety by reference to the full text of the 2025 PIP and the 2025 Non-Employee Director Plan, which are filed as Exhibits 10.1 and 10.2, respectively, and incorporated by reference in this Current Report on Form 8-K.
    2


    Item 5.07.    Submission of Matters to a Vote of Security Holders.
    There were 1,387,662,634 shares of Altria’s common stock represented in person or by proxy at the Annual Meeting, constituting 82.28% of outstanding shares on March 25, 2025, the record date for the Annual Meeting. The matters voted upon at the Annual Meeting and the final voting results are set forth below:
    Proposal 1:    Election of 11 Directors.
    NameForAgainstAbstainBroker Non-Vote
    Ian L.T. Clarke1,033,982,9237,714,3293,465,593342,499,789
    Marjorie M. Connelly1,029,744,40612,333,7333,084,706342,499,789
    R. Matt Davis1,034,528,9337,311,6073,322,305342,499,789
    William F. Gifford, Jr.1,031,009,48511,010,4283,142,932342,499,789
    Debra J. Kelly-Ennis1,009,718,25232,101,3633,343,230342,499,789
    Kathryn B. McQuade1,012,527,81529,329,3273,305,703342,499,789
    George Muñoz1,003,665,66638,136,4643,360,715342,499,789
    Virginia E. Shanks1,033,387,0428,587,7453,188,058342,499,789
    Richard S. Stoddart1,035,420,1606,272,2823,470,403342,499,789
    Ellen R. Strahlman1,034,113,5837,862,3603,186,902342,499,789
    M. Max Yzaguirre1,030,462,52811,422,9953,277,322342,499,789
    All nominees were duly elected as directors of Altria.
    Proposal 2:    Ratification of the Selection of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025.
    ForAgainstAbstain
    1,332,443,94049,918,3875,300,307
    The selection of the independent registered public accounting Firm was ratified.
    Proposal 3:    Non-Binding Advisory Vote to Approve the Compensation of Altria’s Named Executive Officers.
    ForAgainstAbstainBroker Non-Vote
    986,172,10950,685,5548,305,182342,499,789
    The proposal was approved on an advisory basis.
    Proposal 4:    Approval of the 2025 Performance Incentive Plan.
    ForAgainstAbstainBroker Non-Vote
    990,629,15147,123,7157,409,979342,499,789
    The 2025 PIP was approved.
    Proposal 5:     Approval of the 2025 Stock Compensation Plan for Non-Employee Directors.
    ForAgainstAbstainBroker Non-Vote
    1,010,788,04326,417,7707,957,032342,499,789
    The 2025 Non-Employee Director Plan was approved.
    3


    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits
    10.1
    2025 Performance Incentive Plan (incorporated by reference to Exhibit A to Altria Group, Inc.’s Definitive Proxy Statement on Schedule 14A filed on April 3, 2025 (File No. 1-08940)).
    10.2
    2025 Stock Compensation Plan for Non-Employee Directors (incorporated by reference to Exhibit B to Altria Group, Inc.’s Definitive Proxy Statement on Schedule 14A filed on April 3, 2025 (File No. 1-08940)).
    104
    Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

    4



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ALTRIA GROUP, INC.
    By:/s/ W. HILDEBRANDT SURGNER, JR.
    Name:W. Hildebrandt Surgner, Jr.
    Title:Vice President, Corporate Secretary and
    Associate General Counsel
                            

    DATE:    May 19, 2025

    5
    Get the next $MO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    More analyst ratings

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on January 9, 2026 to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20251210780457/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    12/10/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 Third-Quarter and Nine-Months Results; Announces Expanded Share Repurchase Program; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Altria continued to build significant momentum in the third quarter with exciting progress across our businesses," said Billy Gifford, Altria's Chief Executive Officer. "Our core tobacco businesses remained resilient; we advanced our smoke-free portfolio; and we opened new pathways for long-term adjacent growth in international modern oral and U.S. non-nicotine innovation." "We also continue to demonstrate our commitment to returning valu

    10/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Deutsche Bank

    Deutsche Bank downgraded Altria from Buy to Hold

    4/1/25 3:04:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    SEC Filings

    View All

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    12/11/25 7:06:54 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Altria Group Inc.

    10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

    10/30/25 7:21:52 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    10/30/25 7:03:10 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief HR Off. & CCO Whitaker Charles N. was granted 17,168 shares, increasing direct ownership by 10% to 194,464 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    12/11/25 2:35:42 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SVP, Ch.Strategy & Growth Off Newman Heather A. was granted 25,751 shares, increasing direct ownership by 21% to 146,418 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    12/11/25 2:34:51 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SVP, Ch.Strategy & Growth Off Newman Heather A. covered exercise/tax liability with 10,331 shares, decreasing direct ownership by 8% to 120,667 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/25/25 2:41:49 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on January 9, 2026 to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20251210780457/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    12/10/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 Third-Quarter and Nine-Months Results; Announces Expanded Share Repurchase Program; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Altria continued to build significant momentum in the third quarter with exciting progress across our businesses," said Billy Gifford, Altria's Chief Executive Officer. "Our core tobacco businesses remained resilient; we advanced our smoke-free portfolio; and we opened new pathways for long-term adjacent growth in international modern oral and U.S. non-nicotine innovation." "We also continue to demonstrate our commitment to returning valu

    10/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Increases Quarterly Dividend to $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors voted to increase our regular quarterly dividend by 3.9% to $1.06 per share versus the previous rate of $1.02 per share. This increase marks the 60th dividend increase in the past 56 years. The quarterly dividend is payable on October 10, 2025 to shareholders of record as of September 15, 2025. The ex-dividend date is September 15, 2025. The new annualized dividend rate is $4.24 per share, representing a dividend yield of 6.3% based on our closing stock price of $67.58 on August 20, 2025. Today's dividend increase is consistent with our progressive dividend goal that targets mid-single digits dividend per share gro

    8/21/25 1:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director George Muñoz from Board of Directors

    Altria Group, Inc. (Altria) (NYSE:MO) -- George Muñoz, a director of Altria since 2004, notified Altria of his decision to retire from service on our Board of Directors (Board) following the completion of his current term. Consequently, Mr. Muñoz will not stand for re-election to our Board at our 2026 Annual Meeting of Shareholders, which Altria anticipates holding on May 14, 2026. "George has made extensive and significant contributions to Altria over more than 20 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank George for his long-standing and valuable service and wish him the very best upon his retirement." Mr. Muñoz is Chair of the Compensation and Ta

    10/9/25 8:35:00 AM ET
    $LAUR
    $MO
    Other Consumer Services
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

    Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

    2/26/24 4:30:00 PM ET
    $ARIS
    $MO
    $PXD
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care